ArticleOncotarget2020

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma.

Cristina Kinahan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.